Please select the option that best describes you:
Do you take into account ALK fusion variants in your practice for deciding treatment for NSCLC?
Are there atypical ALK fusion partners that indicate sensitivity to ALK inhibitors?
Answer from: Medical Oncologist at Academic Institution
EML4-ALK v3 subtypes and TP53 co-mutations tend to be associated with shorter overall survival in patients, and while we take note of these molecular changes, they have not yet been affected by the selection of frontline therapy. I pay attention to ALK mutations, specifically the G1202R mutation, wh...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I do not. I think they are all sensitive just more so or less so. I am mindful of it but I currently don’t change therapy. I am mindful of this for sure, but don’t do anything different right now.